UK’s Department of Health and Social Care (DHSC) has released six “technical notices” about Brexit relating to batch testing, IT systems, life sciences, and tobacco-related, cell/tissue and blood products, respectively. DHSC Secretary Matt Hancock issued a pair of letters on contingency planning in “the unlikely event we leave the EU without a deal in March 2019” and is asking that pharmaceutical companies have a minimum of six weeks additional supply in the UK. Meanwhile, UK Bioindustry Association (BIA) CEO Steve Bates argues that “endeavoring to deliver on this in less than 200 days will be a massive challenge for industry and the MHRA alike.”
[membership level=”0,4″][The content continues for paid members only.]
Login or Subscribe [/membership][membership level=”1,5,6,7,8,9,10,11,12″][membership]
